Immune defence against EBV and EBV-associated disease.

Research output: Contribution to journalArticle

73 Citations (Scopus)


Epstein-Barr virus (EBV), a B-lymphotropic herpesvirus widespread in the human population and normally contained as an asymptomatic infection by T cell surveillance, nevertheless causes infectious mononucleosis and is strongly linked to several types of human cancer. Here we describe new findings on the range of cellular immune responses induced by EBV infection, on viral strategies to evade those responses and on the links between HLA gene loci and EBV-induced disease. The success of adoptive T cell therapy for EBV-driven post-transplant lymphoproliferative disease is stimulating efforts to target other EBV-associated tumours by immunotherapeutic means, and has reawakened interest in the ultimate intervention strategy, a prophylactic EBV vaccine.
Original languageEnglish
Pages (from-to)258-64
Number of pages7
JournalCurrent Opinion in Immunology
Issue number2
Publication statusPublished - 1 Apr 2011


Dive into the research topics of 'Immune defence against EBV and EBV-associated disease.'. Together they form a unique fingerprint.

Cite this